Dyax Announces Positive Results From Early Stage Trial Of DX-2930

(RTTNews) - Dyax Corp. (DYAX) on Tuesday announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of its investigational product, DX-2930.

Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema attacks.

The ongoing Phase 1b study is a multi-center, randomized, double-blind, placebo-controlled, multiple-ascending dose study designed to assess the safety, tolerability and pharmacokinetics of DX-2930 in hereditary angioedema patients. An analysis of HAE attack rate was also conducted following a pre-specified statistical analysis plan.

Dyax also announced receipt of Fast Track designation from the U.S. Food and Drug Administration for the investigation of DX-2930 for HAE.

Dyax shares surged more than 49% in after hours trading after closing the day's regular trading session at $16.75, down 30 cents or 1.73%.